ClinicalTrials.gov
History of Changes for Study: NCT03444753
An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Can Not be Removed
Latest version (submitted May 17, 2022) on ClinicalTrials.gov
  • A study version is represented by a row in the table.
  • Select two study versions to compare. One each from columns A and B.
  • Choose either the "Merged" or "Side-by-Side" comparison format to specify how the two study versions are to be displayed. The Side-by-Side format only applies to the Protocol section of the study.
  • Click "Compare" to do the comparison and show the differences.
  • Select a version's Submitted Date link to see a rendering of the study for that version.
  • The yellow A/B choices in the table indicate the study versions currently compared below. A yellow table row indicates the study version currently being viewed.
  • Hover over the "Recruitment Status" to see how the study's recruitment status changed.
  • Study edits or deletions are displayed in red.
  • Study additions are displayed in green.
Study Record Versions
Version A B Submitted Date Changes
1 February 20, 2018 None (earliest Version on record)
2 February 22, 2018 Study Status and Study Identification
3 April 2, 2018 Recruitment Status, Study Status, Contacts/Locations and Oversight
4 April 30, 2018 Study Status
5 May 16, 2018 Study Status
6 June 19, 2018 Study Status
7 July 23, 2018 Study Status
8 October 2, 2018 References, Study Status and Contacts/Locations
9 January 30, 2019 Study Status and Contacts/Locations
10 May 30, 2019 Contacts/Locations, Arms and Interventions, Study Status, Eligibility and Study Design
11 July 10, 2019 Study Status and Contacts/Locations
12 August 7, 2019 Contacts/Locations and Study Status
13 September 4, 2019 Contacts/Locations and Study Status
14 November 12, 2019 Study Status and Contacts/Locations
15 March 23, 2020 Contacts/Locations and Study Status
16 November 19, 2021 Contacts/Locations, Study Status, References and Study Design
17 May 17, 2022 Recruitment Status, Study Status, Contacts/Locations, References, Study Design and Eligibility
Comparison Format:
Scroll up to access the controls
Study NCT03444753
Submitted Date:  February 20, 2018 (v1)
Open or close this module Study Identification
Unique Protocol ID: CA039-001
Brief Title: An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Can Not be Removed
Official Title: A Phase I Study of BMS-986299 as Monotherapy and in Combination With Nivolumab and Ipilimumab in Participants With Advanced Solid Cancers
Secondary IDs:
Open or close this module Study Status
Record Verification: February 2018
Overall Status: Not yet recruiting
Study Start: March 1, 2018
Primary Completion: November 14, 2021 [Anticipated]
Study Completion: November 14, 2021 [Anticipated]
First Submitted: February 20, 2018
First Submitted that
Met QC Criteria:		 February 20, 2018
First Posted: February 23, 2018 [Actual]
Last Update Submitted that
Met QC Criteria:		 February 20, 2018
Last Update Posted: February 23, 2018 [Actual]
Open or close this module Sponsor/Collaborators
Sponsor: Bristol-Myers Squibb
Responsible Party: Sponsor
Collaborators:
Open or close this module Oversight
U.S. FDA-regulated Drug: Yes
U.S. FDA-regulated Device: No
Data Monitoring: No
Open or close this module Study Description
Brief Summary: The purpose of this study is to determine whether BMS-986299 both by itself and in combination with Nivolumab and Ipilimumab is safe and tolerable in the treatment of advanced solid tumors. In addition, the ability of study drugs to stimulate an immune response against cancer will be investigated.
Detailed Description:
Open or close this module Conditions
Conditions: Advanced Cancer
Keywords:
Open or close this module Study Design
Study Type: Interventional
Primary Purpose: Treatment
Study Phase: Phase 1
Interventional Study Model: Parallel Assignment
Number of Arms: 2
Masking: None (Open Label)
Allocation: Non-Randomized
Enrollment: 90 [Anticipated]
Open or close this module Arms and Interventions
Arms Assigned Interventions
Experimental: Arm A
BMS-986299
 Biological: BMS-986299
Specified dose on specified day
Experimental: Arm B
BMS-986299 in combination with nivolumab and ipilimumab
 Biological: BMS-986299
Specified dose on specified day
Biological: Nivolumab
Specified dose on specified day
Other Names:
  • Opdivo
  • BMS-936558
Biological: Ipilimumab
Specified dose on specified day
Other Names:
  • Yervoy
  • BMS-734016
Open or close this module Outcome Measures
Primary Outcome Measures:
1. Incidence of dose-limiting toxicities (DLTs)
[ Time Frame: Up to 28 days ]
2. Incidence of adverse events (AEs)
[ Time Frame: Approximately 2 years ]
3. Incidence of serious adverse events (SAEs)
[ Time Frame: Approximately 2 years ]
4. Incidence of AEs leading to discontinuation and deaths
[ Time Frame: Approximately 2 years ]
5. Incidence of clinical laboratory abnormalities
[ Time Frame: Approximately 2 years ]
Secondary Outcome Measures:
1. Maximum observed plasma concentration (Cmax)
[ Time Frame: Approximately 2 years ]
2. Time of maximum observed plasma concentration (Tmax)
[ Time Frame: Approximately 2 years ]
3. Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]
[ Time Frame: Approximately 2 years ]
4. Area under the plasma concentration-time curve from time zero to 24 hours postdose [AUC(0-24)]
[ Time Frame: Approximately 2 years ]
Open or close this module Eligibility
Minimum Age: 18 Years
Maximum Age:
Sex: All
Gender Based:
Accepts Healthy Volunteers: No
Criteria:

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced/metastatic solid tumor and refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for the condition of the participant
  • IO therapy resistant or insensitive tumors
  • Have at least 2 tumor lesions accessible for biopsy
  • Eastern Cooperative Oncology Group Performance Status of 0 or 1

Exclusion Criteria:

  • Primary central nervous system malignancy
  • Participants with other active malignancy requiring concurrent intervention
  • Uncontrolled or significant cardiovascular disease

Other protocol defined inclusion/exclusion criteria could apply
Open or close this module Contacts/Locations
Central Contact Person: Recruiting sites have contact information. Please contact the sites directly. If there is no contact information
Telephone: please email:
Email: Clinical.Trials@bms.com
Central Contact Backup: First line of the email MUST contain NCT # and Site #.
Study Officials: Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Locations:
Open or close this module IPDSharing
Plan to Share IPD:
Open or close this module References
Citations:
Links: Description: BMS Clinical Trial Patient Recruiting
Available IPD/Information:
Scroll up to access the controls Scroll to the Study top
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health & Human Services